All patients receive 24 weeks of induction treatment consisting of:
- 40mg oral dexamethasone, days 1-4, weeks 1,3,5,7,8,11,13 & 15
- 5mg oral lenalidomide daily weeks 3-4, 10mg oral lenalidomide daily weeks 5-24
- 30mg subcutaneous alemtuzumab thrice weekly weeks 7-22
Patients who achieve a CR or PR at 24 weeks may elect to receive an allogeneic stem-cell transplant.
Those responders who decide not to have a transplant will be randomised between receiving lenalidomide maintenance until disease progression or receiving no further trial treatment.
Sorry there are currently no job vacancies
"The experience and treatment I received at the Royal Liverpool Hospital was so fantastic that I had to tell the people involved with my treatment how marvelous they were, so please would you pass on my thanks and gratitude to Professor Neoptolemos and his team of surgeons, the wonderful doctors and nursing staff" - Anon (Participant in ESPAC-3(v2) trial)
Read more Patient stories